Search PubMed⌕ Search

Biomedical subjects

K B Davis

Publications and source records attributed to K B Davis.

At least 19 recordsLinked to original sources
PubMed2001

RB1 genetic testing as a clinical service: a follow-up study.

BACKGROUND: Genetic testing for inherited predisposition to diverse cancers has recently become available as a clinical service. We conducted a follow-up study of the initial series of US families who underwent RB1 genetic testing to evaluate long-term effects of the service. PROCEDURE: We enrolled 52 of 71 eligible families who responded to a follow-up study questionnaire administered 3-10 years after receipt of their RB1 results. Each family had one proband with unilateral, non-familial retinoblastoma, which is associated with a 12% pre-test probability of hereditary retinoblastoma. RB1 testing identified germline RB1 mutations in five patients, lowered the carrier probability to 2% in 21 patients, and did not substantially modify the carrier probability in the remaining 26. RESULTS: Diverse medical specialists offered and arranged for RB1 testing, and their recommendation was the most influential factor in the decision to be tested. Pre-test counseling was provided by ophthalmologists (30), oncologists (11), and geneticists and genetic counselors (11). Most respondents, regardless of test result, were satisfied and perceived gains from their genetic testing. Based on small numbers, families with reduced likelihood of hereditary retinoblastoma reported more positive outcomes. Parents of RB1 carriers were more likely to seek medical services, worry, and decide against having more children. CONCLUSIONS: This study demonstrates the feasibility of follow-up studies of families who had genetic testing. Results from our small series suggest that genetic information and counseling are important components of RB1 clinical genetic testing, and long-term adverse effects of testing are uncommon.

Adult↗
PubMed2001

Localization of estrogen receptor alpha and beta RNA in germinal and nongerminal epithelia of the channel catfish testis.

The germinal epithelium of the anterior region of the channel catfish testis is the site of spermatogenesis, whereas the nongerminal epithelium of the posterior region (seminal vesicle) may play a role in the regulation of seminal fluid composition. The available information indicates that estrogens play a physiological role in the regulation of spermatogenesis and seminal fluid composition in vertebrates. However, the cellular distribution of estrogen receptor (ER) gene expression in the teleost testis is poorly understood. Therefore, the objective of this study was to determine the presence and cellular distribution of ERalpha and ERbeta transcripts in germinal and nongerminal epithelia of the mature testis of channel catfish. RT-PCR of whole-testis RNA extracts showed that ERalpha and ERbeta RNAs are present in the mature testis. In situ hybridization of histological sections of the germinal epithelium showed that primary spermatocytes contain little or no ERalpha or ERbeta RNA. However, both ER transcripts were present in secondary spermatocytes and spermatids and their levels were relatively high in mature sperm. The columnar epithelium of the seminal vesicle also contained ERalpha and ERbeta RNA. The ER RNAs in epithelial cells of the seminal vesicle were not evenly distributed throughout the cytoplasm but seemed to concentrate in their apical region, near the nucleus. In conclusion, ERalpha and ERbeta genes are coexpressed in germinal and nongerminal epithelia of the mature testis of channel catfish and seem to be developmentally regulated in spermatocytes. These observations are consistent with the concept that estrogens, via interaction with ERalpha and ERbeta, participate in the regulation of male gamete development and fertility.

Animals↗
PubMed2001

Early identification of divergent performance in congenital cardiac surgery.

OBJECTIVES: Heterogeneous caseload and poorly quantified risk stratification make it difficult to monitor outcomes in congenital cardiac surgery. Reliance on formal statistical hypothesis testing may lead to substantial delays before a pattern of poor outcome can be established. Here, we report alternative methods for alerting surgeons to potential problems at an earlier stage. METHODS: Graphical methods developed for monitoring adult cardiac surgery have been adapted for use in congenital cardiac surgery. To illustrate their potential, we have retrospectively examined mortality data for a single surgeon involving 315 cases. Partial risk adjustment has been carried out according to patient's age and the open/closed categorization of the surgical procedure. Additional information has been derived by ranking procedures in order of their complexity and displaying the proportion of the surgeon's cases in each complexity stratum. RESULTS: The display of a surgeon's mortality data adjusted for age and open/closed category provides an easily understood chart of performance and allows one to identify periods when performance appears divergent, relative to the surgeon's own overall standards. Cases carried out during such periods can then be scrutinized by alternative methods. One such method is to examine caseload complexity during the periods of apparent divergent performance compared with other periods. CONCLUSIONS: These methods, while in no way representing formal statistical tests, provide a means that can alert surgeons to potential problems and help to identify sequences of cases that might benefit from further scrutiny.

Age Factors↗
PubMed2000

Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial.

CONTEXT: Although niacin increases low levels of high-density lipoprotein cholesterol (HDL-C), which frequently accompany diabetes, current guidelines do not recommend use of niacin in patients with diabetes because of concerns about adverse effects on glycemic control; however, this is based on limited clinical data. OBJECTIVE: To determine the efficacy and safety of lipid-modifying dosages of niacin in patients with diabetes. DESIGN AND SETTING: Prospective, randomized placebo-controlled clinical trial conducted in 6 clinical centers from August 1993 to December 1995. PARTICIPANTS: A total of 468 participants, including 125 with diabetes, who had diagnosed peripheral arterial disease. INTERVENTIONS: After an active run-in period, participants were randomly assigned to receive niacin (crystalline nicotinic acid), 3000 mg/d or maximum tolerated dosage (n = 64 with diabetes; n = 173 without diabetes), or placebo (n = 61 with diabetes; n = 170 without diabetes) for up to 60 weeks (12-week active run-in and 48-week double-blind). MAIN OUTCOME MEASURES: Plasma lipoprotein, glucose, hemoglobin A(1c) (HbA(1c)), alanine aminotransferase, and uric acid levels; hypoglycemic drug use; compliance; and adverse events, in patients with diabetes vs without who were receiving niacin vs placebo. RESULTS: Niacin use significantly increased HDL-C by 29% and 29% and decreased triglycerides by 23% and 28% and low-density lipoprotein cholesterol (LDL-C) by 8% and 9%, respectively, in participants with and without diabetes (P<.001 for niacin vs placebo for all). Corresponding changes in participants receiving placebo were increases of 0% and 2% in HDL-C and increases of 7% and 0% in triglycerides, and increases of 1% and 1% in LDL-C. Glucose levels were modestly increased by niacin (8.7 and 6.3 mg/dL [0.4 and 0.3 mmol/L]; P =.04 and P<.001) in participants with and without diabetes, respectively. Levels of HbA(1c) were unchanged from baseline to follow-up in participants with diabetes treated with niacin. In participants with diabetes treated with placebo, HbA(1c) decreased by 0.3% (P =.04 for difference). There were no significant differences in niacin discontinuation, niacin dosage, or hypoglycemic therapy in participants with diabetes assigned to niacin vs placebo. CONCLUSIONS: Our study suggests that lipid-modifying dosages of niacin can be safely used in patients with diabetes and that niacin therapy may be considered as an alternative to statin drugs or fibrates for patients with diabetes in whom these agents are not tolerated or fail to sufficiently correct hypertriglyceridemia or low HDL-C levels. JAMA. 2000;284:1263-1270

Aged↗
PubMed2000

Effect of niacin, warfarin, and antioxidant therapy on coagulation parameters in patients with peripheral arterial disease in the Arterial Disease Multiple Intervention Trial (ADMIT).

BACKGROUND: Patients with peripheral arterial disease (PAD) have high rates of cardiovascular morbidity and mortality, including that caused by associated coronary heart disease and cerebrovascular disease. Previous studies have shown that coagulation parameters are altered in PAD and that altered coagulation may play a critical role in the susceptibility to cardiovascular complications in PAD. It is therefore important to assess the effect of secondary prevention measures on coagulation in patients with PAD. The Arterial Disease Multiple Intervention Trial (ADMIT), a multicenter, randomized, placebo-controlled trial, was conducted to determine the feasibility of a combined lipid-modifying, antioxidant, and antithrombotic treatment regimen in patients with PAD. The objective of this study was to assess the effect of the ADMIT interventions on coagulation. METHODS: ADMIT participants were randomly assigned to low-dose warfarin, niacin, and antioxidant vitamin cocktail or corresponding placebos in a 2 x 2 x 2 factorial design. Specialized coagulation studies were performed in a subset of 80 ADMIT participants at baseline and after 12 months of treatment. RESULTS: Low-dose warfarin (1 to 4 mg/d) resulted in a significant decrease in factor VIIc (P <.001) and in plasma F1.2 (P =.001). Unexpectedly, niacin treatment also resulted in significant decrease in both fibrinogen (48 mg/dL; P <.001) and F1.2 (P =.04). von Willebrand factor increased after antioxidant vitamin treatment (P =.04). CONCLUSIONS: A regimen of low-dose warfarin effectively modifies coagulation in patients with PAD. Niacin also favorably modifies fibrinogen and plasma F1.2. Niacin, in addition to its lipid effects, modifies abnormal coagulation factors that accompany PAD.

Aged↗
PubMed2000

Effective and safe modification of multiple atherosclerotic risk factors in patients with peripheral arterial disease.

BACKGROUND: Patients with peripheral arterial disease (PAD) are at an increased risk of cardiovascular mortality and morbidity and thus are an excellent group in whom to evaluate the feasibility and the effect of an aggressive multifactorial intervention on atherosclerotic vascular disease risk factors. The Arterial Disease Multiple Intervention Trial (ADMIT) was designed to determine the efficacy, safety, and compliance of an multifactorial therapy on selected atherosclerotic disease risk factors in patients with PAD. METHODS: By a 2 x 2 x 2 factorial design, eligible participants (N = 468) were randomly assigned to low-dose warfarin, antioxidant vitamins, and niacin or its corresponding placebo, and followed up for 1 year. All participants were encouraged to use aspirin. Pravastatin was added to the drug regimen for those who needed to reduce LDL cholesterol to recommended levels. RESULTS: Niacin increased HDL cholesterol levels by 30%, with the majority of effect achieved at a dosage of 500 mg twice daily. Warfarin had an anticoagulant effect. The antioxidant vitamins resulted in a significant increase in vitamin E, C, and beta-carotene plasma levels. Overall, compliance was high and few adverse effects were reported. CONCLUSIONS: ADMIT demonstrates that it is both feasible and safe to modify multiple atherosclerotic disease risk factors effectively with intensive combination therapy in patients with PAD.

Aged↗
PubMed1999

Rationale and design of the Arterial Disease Multiple Intervention Trial (ADMIT) pilot study.

The primary objectives of the pilot study were to: (1) evaluate the feasibility of recruiting patients with peripheral arterial disease (PAD); (2) measure the efficacy and safety of high-density lipoprotein (HDL)-raising treatment, low-density lipoprotein (LDL)-lowering therapy, antioxidant therapy, antithrombotic therapy, and their combinations; and (3) assess adherence to a complex multiple drug regimen. Secondary objectives included measurement of the effect of the interventions on prespecified biochemical markers, maintenance of therapy masking (in particular with niacin), and measurement of the intervention's impact on functional status and on quality of life. To date, no secondary prevention trial has been conducted specifically among patients with PAD. Intermittent claudication affects about 0.5% to 1.0% of persons aged >35 years. There is a striking increase in incidence of PAD with age, particularly among those aged >50 years in both sexes, although men are twice as likely as women to develop PAD. The Arterial Disease Multiple Intervention Trial was a double-blind randomized pilot trial of 468 participants with documented PAD. A 2 x 2 x 2 factorial design was used to evaluate the effect of 3 interventions. The pilot incorporated several major novel design features: first, the use of a simple noninvasive method (measurement of ankle brachial index) to identify a population with either symptomatic or asymptomatic PAD; and second, a lipid modifying strategy to increase HDL with nicotinic acid in the intervention group while lowering LDL levels equally with an hydroxymethylglutaryl-coenzyme A reductase inhibitor as needed in the intervention and control group. Two other arms, the antioxidant arm (consisting of beta-carotene and vitamins E and C) and the antithrombotic arm (using warfarin) were also added. Adherence to therapy was measured by pill count, and success in treatment was measured by the proportion of values in target range for HDL, LDL, and the international normalized ratio.

Adult↗
PubMed1999

Scent-marking and cortisol response in the small-eared bushbaby (Otolemur garnettii).

Among prosimians, some types of scent-marking may serve as displacement activities that reduce physiological arousal in stressful situations. Type and frequency of scent-marking was measured for 22 male small-eared or Garnett's bushbabies (Otolemur garnettii) exposed to a novel open field environment, with and without novel objects. Rates of foot rubbing, chest rubbing, urine washing, flank rubbing, and ano-genital marking were measured. Foot and chest rubbing constituted 92.5% of responses. Type and frequency of scent-marking was compared to the magnitude of the animals' cortisol responses in a separate test of restraint stress. Only foot and chest rubbing were systematically related to cortisol levels. The animals that performed these behaviors more in the novel environment also exhibited lower cortisol responses to restraint stress. These results suggest that bushbabies that characteristically employ behavioral coping strategies have a reduced physiological response to psychological stressors.

Animals↗
PubMed1999

Compliance to multiple interventions in a high risk population.

PURPOSE: Assess compliance with study medications and examine reasons for noncompliance. Individuals with peripheral arterial disease present the clinician with a unique combination of symptoms and therapeutic needs; the treatment of this population has not been adequately studied. METHODS: The Arterial Disease Multiple Intervention Trial was a randomized double-blind placebo-controlled trial that randomized 468 participants to a combination of antioxidants, niacin and warfarin or matching placebos. Men and women (mean age 65 yrs) with peripheral arterial disease and low-density lipoprotein (LDL) < 190 mg/dl were enrolled and followed for one year. Compliance to the study medications was measured by pill count for each medication. An overall measure of compliance was determined by combining pill counts from all study visits. RESULTS: Mean overall pill counts ranged from 88 to 94% in the eight treatment groups. No statistically significant differences were found in mean pill counts over time or between active and placebo groups. History of coronary artery disease and number of follow-up visits were associated with higher overall pill counts while low compliance during screening was associated with lower counts during follow-up. Participants with an overall mean pill count < 80% had more adverse events compared to those with a higher count. Side effects were reported as the reason for missing pills significantly more often in the active versus placebo niacin group. CONCLUSIONS: Individuals with peripheral arterial disease were able to comply with the complex drug regimen. The ability of this drug combination to reduce cardiovascular events and improve quality of life warrants study.

Adult↗
PubMed1999

Corrected count increment and percent platelet recovery as measures of posttransfusion platelet response: problems and a solution.

BACKGROUND: Corrected count increment (CCI) and percent platelet recovery (PPR) are measures of response to platelet transfusion that "correct" the count increment for blood volume and number of platelets transfused. Their potential for data distortion is described, and a regression analysis is suggested that is more informative and avoids the inherent problems associated with using ratios as outcome measures. STUDY DESIGN AND METHODS: Data from the first platelet transfusion for 585 patients from the Trial to Reduce Alloimmunization to Platelets (TRAP) were used to model methods of analyzing posttransfusion platelet response. RESULTS: By linear regression analysis, unfiltered platelet components gave a greater posttransfusion increment on average (p = 0.001), but filtered platelets gave a greater increment per platelet transfused (p = 0.003). In contrast, CCI and PPR showed no difference between filtered and unfiltered platelets (p = 0.36 and p = 0.29, respectively) because they combined the effects of dose, filtration, and patient size. Slightly fewer patients are required for a study analyzed by regression analysis. CONCLUSION: Regression analysis of posttransfusion platelet increments should be used instead of CCI or PPR to compare the efficacy of platelet components. CCI and PPR should not be used to define platelet refractoriness as a study outcome, because these measures are biased in favor of platelet preparation techniques that provide fewer platelets.

Blood Platelets↗
PubMed1996

Coronary bypass surgery with internal-thoracic-artery grafts--effects on survival over a 15-year period.

BACKGROUND: Aortocoronary bypass surgery has been performed most often with the patient's saphenous vein as the conduit. The internal-thoracic-artery graft, which has superior patency rates, has been shown to have clinical advantages, but it is not known how long these advantages persist. METHODS: We identified all the patients in the registry of the Coronary Artery Surgery Study who had undergone first-time coronary-artery bypass grafting. Those with internal-thoracic-artery bypass grafts (749 patients) were compared with those with saphenous-vein bypass grafts only (4888 patients) with respect to survival over a 15-year follow-up period. RESULTS: In a multivariate analysis to account for differences between the two groups, the presence of an internal-thoracic-artery graft was an independent predictor of improved survival and was associated with a relative risk of dying of 0.73 (95 percent confidence interval, 0.64 to 0.83). This improved survival was also observed in subgroups including patients 65 years of age or older, both men and women, and patients with impaired ventricular function. The survival curves of the two groups showed further separation over the years of follow-up, with a more marked downsloping after eight years in the curve for the group with saphenous-vein grafts only than in that for the group with internal-thoracic-artery grafts. CONCLUSIONS: As compared with saphenous-vein coronary bypass grafts, internal-thoracic-artery grafts conferred a survival advantage throughout a 15-year follow-up period. The survival advantage increased with time, suggesting that the initial selection of the conduit was a more important factor in survival than problems appearing long after surgery, such as the progression of coronary disease.

Aged↗
PubMed1996

Sex-linkage of glucosephosphate isomerase-B and mapping of the sex-determining gene in channel catfish.

Sex-linkage of glucosephosphate isomerase-B (GPI-B) was observed in five experimental matings between heterozygous male and homozygous female channel catfish (Ictalurus punctatus). Offspring phenotypes for GPI-B were 40.8% heterozygous male and 43.0% homozygous female, while recombinant offspring were 7.4% homozygous male and 8.8% heterozygous female. Thus, GPI-B and the sex-determining gene (SDG) were linked and had a recombination rate of 16.2%. This linkage was designated I. punctatus linkage group XXIX. The gene-centromere distance (1.66 cM) of SDG, estimated in six gynogenetic families derived from XY females, indicated that SDG resides very close to the centromere. Based on estimates of these genetic distances, a chromosomal order of GPI-B-centromere-SDG was proposed. Additionally, joint segregation of GPI-A and SDG in two experimental matings indicated no genetic linkage between GPI-A and sex. These genetic relationships were compared to those reported in other teleost taxa with regard to evolutionary conservation of ancestral gene arrangements.

Animals↗
PubMed1995

Comparison of surgical and medical group survival in patients with left main coronary artery disease. Long-term CASS experience.

BACKGROUND: Observational and randomized studies designed to compare surgical and medical therapies in patients with left main coronary artery disease (LMCD) have shown that coronary artery bypass graft (CABG) surgery prolongs life in most patients with LMCD. The present report of 1484 patients with LMCD in the Coronary Artery Surgery Study (CASS) Registry extends the originally published 5-year surgical and medical group survival analysis to more than 16 years of follow-up and permits analysis of LMCD patient subgroups. METHODS AND RESULTS: The CASS Registry contains 1484 patients with > or = 50% left main coronary artery stenosis initially treated with either surgical or nonsurgical therapy. The 15-year cumulative survival estimates were 37% for the 1153 patients in the surgical group compared with 27% for the 331 patients in the medical group. Median survival in the surgical group was 13.3 years (12.8 to 13.8 years, 95% confidence limits) compared with only 6.6 years (5.4 to 7.9 years) in the medical group (difference, 6.7 years; P < .0001). Median survival was also significantly longer in the surgical group stratified by age, sex, anginal class, left ventricular (LV) function, coronary anatomy, and the extent of LMCD. However, CABG surgery did not significantly prolong median survival in patient subgroups with (1) left main coronary stenosis of 50% to 59%; (2) normal LV systolic function; (3) normal or mildly abnormal LV systolic function and a right coronary artery stenosis > or = 70%; and (4) a nonstenotic (< or = 70%) right coronary artery. The 15-year cumulative survival for patients with normal LV systolic function in the surgical and medical groups was 42% and 51%, respectively. Median survival was 14.7 years in the surgical group and > 15 years in the medical group (P = NS). In patients with normal LV systolic function and a right coronary artery stenosis > or = 70%, the 15-year cumulative survival rates were also similar in the surgical and medical groups (40% and 48%, respectively). Median survival was 14.3 years in the surgical group and 14.2 years in the medical group (P = NS). The 15-year cumulative survival estimates for all subgroups were affected by convergence of the surgical and medical survival group curves owing to a disproportionate increase in the late surgical group mortality. Overall, 25% of patients in the medical group ultimately underwent CABG surgery. If all medical group patients had survived long enough, about 47% would be estimated to have had surgery by 15 years. CONCLUSIONS: This report, which extends follow-up of more than 16 years in CASS Registry patients with LMCD, shows that CABG surgery prolongs life in most clinical and angiographic subgroups. However, median survival was not prolonged by CABG surgery in patients with normal LV systolic function, even if a significant right coronary artery stenosis (> or = 70%) also was present. These results extend our understanding of the natural history of LMCD and permit a more accurate estimate of long-term surgical and medical group survival.

Cohort Studies↗
PubMed1995

Comparison of surgical and medical group survival in patients with left main equivalent coronary artery disease. Long-term CASS experience.

BACKGROUND: Combined severe proximal left anterior descending and proximal left circumflex coronary artery disease, or left main equivalent (LMEQ) disease, defines a prognostic high-risk angiographic subset of patients with chronic ischemic heart disease. While numerous observational and randomized clinical trials showed prolonged survival in surgically compared with medically treated patients with left main coronary artery disease, relatively few observational studies compared surgical and medical therapies in patients with LMEQ disease. The present report of 912 patients with LMEQ disease in the Coronary Artery Surgery Study (CASS) Registry extends the originally published 5-year surgical and medical group survival analysis to more than 16 years of follow-up and permits analysis of LMEQ patient subgroups. METHODS AND RESULTS: The CASS Registry contains 912 patients with LMEQ disease, defined as combined stenoses of > or = 70% in the proximal left anterior descending coronary artery before the first septal perforator and proximal circumflex coronary artery before the first obtuse marginal branch, initially treated with either surgical or nonsurgical therapy. The 15-year cumulative survival estimates were 44% for the 630 patients in the surgical group and 31% for the 282 patients in the medical group. Median survival in the surgical group was 13.1 years (12.7 to 14.1 years, 95% confidence limits) compared with only 6.2 years (4.8 to 7.9 years) in the medical group (difference, 6.9 years; P < .0001). Median survival was also significantly longer in the surgical group stratified by age, sex, anginal class, left ventricular (LV) function, and coronary anatomy. However, coronary artery bypass graft (CABG) surgery did not significantly prolong median survival in patient subgroups with (1) normal LV systolic function, even if a significant right coronary artery stenosis (> or = 70%) also was present, and (2) mildly abnormal (LV score, 6 to 10) LV systolic function. The 15-year cumulative survival in patients with normal LV systolic function in the surgical and medical groups was 63% and 54%, respectively. Median survival was > 15 years in both the surgical and medical groups (P = NS). In patients with normal LV systolic function and right coronary artery stenosis > or = 70%, the 15-year cumulative survival was also similar in the surgical and medical groups (63% and 53%, respectively). Median survival was > 15 years in both the surgical and medical groups (P = NS). The 15-year cumulative survival estimates in all subgroups were affected by convergence of the surgical and medical group survival curves caused by a disproportionate increase in late surgical group mortality. Overall, 26% of patients in the medical group ultimately underwent CABG surgery. If all medical group patients had survived long enough, about 65% would be estimated to have had surgery by 15 years. When the CASS Registry patients with LMEQ disease who participated in the randomized trial or who were randomizable were analyzed, CABG surgery did not prolong the 15-year cumulative survival estimates compared with nonsurgical therapy for randomized (71% versus 67%, respectively) and for randomizable patients (62% versus 92%, respectively) with an LV ejection fraction > or = 50%. CONCLUSIONS: This report, which extends follow-up of more than 16 years in CASS Registry patients with LMEQ disease, shows that CABG surgery prolongs life in most clinical and angiographic subgroups. However, median survival was not prolonged by CABG surgery in patients with normal LV systolic function, even if a significant right coronary artery stenosis (> or = 70%) also was present or in patients with an LV ejection fraction > or = 50% who participated in the CASS randomized trial or who were randomizable.

Coronary Angiography↗
PubMed1995

The utility of clinical, electrocardiographic, and roentgenographic variables in the prediction of left ventricular function.

To determine the clinical value of simple, widely available variables in estimating left ventricular (LV) function, we performed an analysis on 14,507 patients presenting with chest pain who were enrolled in the Coronary Artery Surgery Study registry. Of these patients, 4,034 had a normal electrocardiogram, and of these, 91.8% had an LV ejection fraction (EF) > 0.50, 7.6% had an EF of 0.36 to 0.50, and only 0.6% had an EF < or = 0.35. The presence of T-wave abnormalities (with normal QRS), left bundle branch block, electrocardiographic evidence of LV hypertrophy or myocardial infarction, cardiomegaly on chest roentgenogram, basilar rales, or third heart sound significantly decreased the likelihood of normal LVEF. Based on these clinical variables, a logistic regression model with a sensitivity of 68% and a specificity of 74% for identifying subjects with normal EF was developed. It was concluded that in patients with chest pain, consideration of such readily available clinical data provides useful information and may decrease the need for more expensive imaging methods.

Electrocardiography↗
PubMed1995

Comparison of 15-year survival for men and women after initial medical or surgical treatment for coronary artery disease: a CASS registry study. Coronary Artery Surgery Study.

OBJECTIVES: This study compared the rates of coronary artery bypass graft surgery and 15-year survival for men and women after initial medical or surgical management. BACKGROUND: There has been concern that women with coronary artery disease are managed differently than men and that men and women have a different prognosis. The Coronary Artery Surgery Study (CASS) registry is a large data base of well characterized patients with long-term follow-up. METHODS: Patients underwent cardiac catheterization at 1 of 15 hospitals during 1974 to 1979. Bypass surgery rates were based on 12,452 men and 2,366 women. Survival results were based on 6,018 men and 1,095 women with operable coronary artery disease and initial medical management and 6,922 men and 1,291 women initially managed surgically. RESULTS: At 15 years, bypass surgery rates were 75% for men and 72% for women (p = 0.91). The rates remained similar after adjustment for clinical and angiographic variables. The 15-year survival rate was 50% for men and 49% for women with initial medical treatment (p = 0.53) and 52% for men and 48% for women (p = 0.004) with initial surgical treatment, a difference similar to that for operative mortality (men 2.5%, women 5.3%, p < 0.0001). Survival was improved by bypass surgery in most subgroups, with largest relative risks for high risk patients. Relative risks were similar for men and women. CONCLUSIONS: The rate of bypass surgery did not differ between men and women. There were few differences in the survival of men and women. In general, both men and women with initial surgical treatment survived longer, although benefits were clinically and statistically significant only in those at high risk. The benefit was similar in both men and women.

Cardiac Catheterization↗
PubMed1995

Recurrence of angina after coronary artery bypass surgery: predictors and prognosis (CASS Registry). Coronary Artery Surgery Study.

OBJECTIVES: This study sought to define the predictors and prognosis of postoperative angina in patients undergoing coronary artery bypass surgery. BACKGROUND: Angina recurs in the first postoperative year in 20% to 30% of patients after coronary artery bypass surgery. The Coronary Artery Surgery Study Registry provides an opportunity to study the predictors and prognosis of postoperative angina in a large sample. METHODS: All patients with isolated coronary artery bypass surgery in the registry were identified, and anginal status was determined on a yearly basis. The influence of angina on mortality, recurrent myocardial infarction and need for reoperation was determined. RESULTS: Angina recurred in the first year in 24% of patients and by the sixth year in 40%. The significant predictors in a multivariate analysis were minimal coronary artery disease, preoperative angina, use of vein grafts only, previous myocardial infarction, incomplete revascularization, female gender, smoking and younger age. In subsequent years important predictors were angina in the first postoperative year, female gender, younger age and incomplete revascularization. The presence of angina in the first postoperative year was associated with more frequent myocardial infarction (p = 0.04) and greater need for reoperation (p = 0.003) but did not affect survival during the 6-year follow-up period. CONCLUSIONS: These findings show that the predictors of postoperative angina are features that are or could be predicted before bypass surgery. Thus, patients with these features before bypass surgery could be advised that they would be more likely to experience postoperative angina than those without these features. Postoperative angina is associated with an increased risk of late myocardial infarction and reoperation.

Angina Pectoris↗